Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid

Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.

Rheumatoid Arthritis Pathophysiology